{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:03:12Z","timestamp":1792011792606,"version":"4.4.0"},"reference-count":49,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["139777"],"award-info":[{"award-number":["139777"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and ABBV-322, may represent a novel therapeutic strategy in MM. EGFR and mAb806 epitope expressions in mesothelioma cell lines were evaluated using an array of binding assays, and the in vitro cell effects of ABT-414 and ABBV-322 were determined. In vivo therapy studies were conducted in mesothelioma xenograft and patient-derived xenograft (PDX) tumor models. We also performed biodistribution and imaging studies to allow the quantitative targeting of MM by mAb806 using a 89Zr-labeled immunoconjugate\u2014ch806. A high EGFR expression was present in all mesothelioma cell lines evaluated and mAb806 binding present in all cell lines, except NCIH-2452. ABT-414 and ABBV-322 resulted in significant tumor growth inhibition in MM models with high EGFR and mAb806 epitope expressions. In contrast, in an EGFR-expressing PDX model that was negative for the mAb806 epitope, no growth inhibition was observed. We demonstrated the specific targeting of the mAb806 epitope expressing MM tumors using 89Zr-based PET imaging. Our data suggest that targeting EGFR in MM using specific ADCs is a valid therapeutic strategy and supports further investigation of the mAb806 epitope expression as a predictive biomarker.<\/jats:p>","DOI":"10.3390\/ph13100289","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T09:39:25Z","timestamp":1601631565000},"page":"289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma"],"prefix":"10.3390","volume":"13","author":[{"given":"Puey-Ling","family":"Chia","sequence":"first","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia"},{"name":"Department of Medical Oncology, Austin Health, Melbourne, Victoria 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Department of Medical Oncology, Austin Health, Melbourne, Victoria 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Plenty Rd &amp;, Kingsbury Dr, Bundoora, Victoria 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-5405","authenticated-orcid":false,"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu-An","family":"Pham","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui K.","family":"Gan","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia"},{"name":"Department of Medical Oncology, Austin Health, Melbourne, Victoria 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Plenty Rd &amp;, Kingsbury Dr, Bundoora, Victoria 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cao","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8384-2403","authenticated-orcid":false,"given":"Ingrid J. G.","family":"Burvenich","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Reilly","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia"},{"name":"Department of Medical Oncology, Austin Health, Melbourne, Victoria 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Plenty Rd &amp;, Kingsbury Dr, Bundoora, Victoria 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Plenty Rd &amp;, Kingsbury Dr, Bundoora, Victoria 3086, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja11.10125","article-title":"Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation","volume":"195","author":"Olsen","year":"2011","journal-title":"Med. J. Aust."},{"key":"ref_2","unstructured":"Landrigan, P.J., and Kazemi, H. (1991). Third Wave of Asbestos Disease, New York Academy of Sciences."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-008-0384-4","article-title":"Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma","volume":"134","author":"Okuda","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations","volume":"104","author":"Rena","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest oncology group study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"ref_9","unstructured":"Clinical Trials.gov (2020, October 01). Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma (NCT01592383), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01592383."},{"key":"ref_10","unstructured":"University Hospital, G. (2020, October 01). Study of Cetuximab Combined with Cisplatin or Carboplatin\/Pemetrexed as First Line Treatment in Patients with Malignant Pleural Mesothelioma (MesoMab NCT00996567), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00996567."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30375","DOI":"10.1074\/jbc.M401218200","article-title":"Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor","volume":"279","author":"Johns","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","article-title":"Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy","volume":"72","author":"Gan","year":"2012","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10637-015-0234-6","article-title":"A phase 1 study of ABT-806 in subjects with advanced solid tumors","volume":"33","author":"Cleary","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","article-title":"ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope","volume":"15","author":"Phillips","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","article-title":"Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: Results from a multi-center, international study","volume":"80","author":"Bent","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/neuonc\/noy091","article-title":"Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients withEGFR-amplified, recurrent glioblastoma: Results from an international phase I multicenter trial","volume":"21","author":"Lassman","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2017.35.15_suppl.2510","article-title":"Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR","volume":"35","author":"Calvo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_20","first-page":"1","article-title":"A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR","volume":"2020","author":"Cleary","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Anderson, M.G., Falls, H.D., Mitten, M.J., Oleksijew, A., Vaidya, K.S., Boghaert, E.R., Gao, W., Palma, J.P., Cao, D., and Chia, P.-L. (2020). Targeting multiple EGFR expressing tumors with a highly potent tumor-selective antibody drug conjugate. Mol. Cancer Ther.","DOI":"10.1158\/1535-7163.MCT-20-0149"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody\u2013drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.bjc.6602470","article-title":"Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR","volume":"92","author":"Panousis","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nayak, T.K., Garmestani, K., Milenic, D.E., Baidoo, K.E., and Brechbiel, M.W. (2011). HER1-Targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018198"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3892\/ijo.2012.1607","article-title":"Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma","volume":"41","author":"Kurai","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jtho.2016.03.001","article-title":"EGFR status in mesothelioma: Possible implications for the efficacy of anti-EGFR and anti-MET therapies","volume":"11","author":"Salvi","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_28","first-page":"17","article-title":"Development and characterization of 89Zr-labeled panitumumab for immuno\u2013positron emission tomographic imaging of the epidermal growth factor receptor","volume":"12","author":"Chang","year":"2013","journal-title":"Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Izquierdo-S\u00e1nchez, V., Mu\u00f1iz-Hern\u00e1ndez, S., V\u00e1zquez-Becerra, H., Yepez, J.P., Romero-Pi\u00f1a, M.E., Arrieta, O., and Medina, L.A. (2018). Biodistribution and tumor uptake of 67Ga-nimotuzumab in a malignant pleural mesothelioma xenograft. Molecules, 23.","DOI":"10.3390\/molecules23123138"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.115.169839","article-title":"Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a","volume":"57","author":"Burvenich","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","article-title":"89Zr-DFO-J591 for immune PET imaging of prostate-specific membrane antigen (PSMA) expression In Vivo","volume":"51","author":"Holland","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.108.060392","article-title":"Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging","volume":"50","author":"Dijkers","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.31304","article-title":"Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor","volume":"124","author":"Goss","year":"2018","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.0611693104","article-title":"A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors","volume":"104","author":"Scott","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01 Randomized Phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc3944","article-title":"Examining the utility of patient-derived xenograft mouse models","volume":"15","author":"Aparicio","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.bjc.6693248","article-title":"Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells","volume":"81","author":"Bernard","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Martarelli, D., Catalano, A., Procopio, A., Orecchia, S., Libener, R., and Santoni, G. (2006). Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-130"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1089\/hum.2008.036","article-title":"Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma","volume":"19","author":"Kelly","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","first-page":"511","article-title":"Biological effects In Vitro of monoclonal antibodies to human epidermal growth factor receptors","volume":"1","author":"Sato","year":"1983","journal-title":"Mol. Boil. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non\u2013small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"ref_49","first-page":"4474","article-title":"Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/10\/289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:58Z","timestamp":1760177758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/10\/289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ph13100289"],"URL":"https:\/\/doi.org\/10.3390\/ph13100289","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]}}}